A recent study suggests that individuals who come off new GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds at a significantly accelerated pace than those who halt conventional lifestyle regimens.
Research printed in a prominent health publication points out that while overweight individuals can lose substantial amounts of their total mass while on the medication, the mass is regained at an average rate of nearly a kilo each month once they quit.
"Individuals purchasing such drugs must be cognizant of the potential of rapid weight regain when the therapy ends," stated expert Dr. Susan Jebb.
This pace of recovery means a return to pre-treatment weight in about a year and a half.
Analyzing Treatments
The research, which reviewed dozens of studies involving over 9,000 of participants, contrasted the outcomes of the injectable medications with conventional dieting.
The team point out that people who shed pounds through dieting typically have a less rapid weight regain—approximately 100 grams monthly—once they finish.
The Reason for the Fast Rebound
Nutrition scientists believe the mode of action of the jabs explains the amplified rebound.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Sustained high doses of the hormone concentrations several times higher than normal could lead to the body to produce less of its own natural GLP-1, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert.
"Stopping of this medication leads to appetite is uncontrolled, making binge eating a significant risk."
A Lifelong Condition?
Health authorities recommend the jabs for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Many experts contend that, due to the high risk of weight regain, the therapy should be considered long-term.
This view is supported by drug manufacturers, who note that the findings "underscore the persistent character of excess weight," similar to managing diseases like diabetes.
User Accounts
Individuals who have discontinued the medication describe a sudden resurgence of hunger.
"It was like a switch that goes on and you become extremely hungry," recalled one woman.
This difficulty is worsened if users have not adopted sustainable lifestyle or habit changes during treatment.
Growing Interest
Figures suggest that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is greater among females than men.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a permanent fix and long-term success relies on integrated lifestyle management.
